Prognostic impact of blood product transfusion in VA and VV ECMO

Abstract

Background:

Extracorporeal membrane oxygenation (ECMO) is an accepted and reliable technique to provide temporary circulatory and/or respiratory support. Our objective was to describe the transfusion requirements in ECMO recipients. Secondarily, we addressed the effect of indications for ECMO on transfusion requirements and the baseline factors associated with worse survival.

Methods:

We reviewed the prospectively collected data of 509 patients receiving venoarterial (VA) or venovenous (VV) ECMO therapy (2005-2016). Follow-up was prospectively conducted. Data were prospectively entered in the Rennes ECMO database.

Results:

VA ECMO was employed in 81% of cases; indications were post-cardiotomy myocardial failure in 28% of cases, post-heart transplantation (early graft failure) in 13.2% and cardiogenic shock in 149 (36.4%). VV ECMO was employed in the remaining patients. Average follow-up was 80.25 ± 85.13 days and was 100% complete. In the VA and VV groups, survival at the 30th post-implantation day was 58.3% and 71.1%, respectively, and survival at 6 months was 40.5% and 50.5%, respectively. Platelets and prothrombin time (PT) levels were significantly lower in the VA ECMO group at implantation (p<0.001). VA ECMO patients had a higher rate of thrombotic/haemorrhagic complications (p<0.001) and received both fresh frozen plasma (FFP) (60.5% vs. 31.8% p<0.001) and platelet units (Plt) (61.7% vs. 34.1% p<0.001) more frequently than VV ECMO patients. Post-cardiotomy and post-transplantation patients had significantly higher rates of transfusion of packed red blood cells (pRBC), FFP and Plt than other VA ECMO cases (p<0.001, all). Mortality was equal or greater than 80% among patient subgroups who received more than 19 pRBC, 5 Plt and/or 12 FFP.

Conclusions:

An ECMO program is associated with important consumption of blood products. VA ECMO patients have a greater transfusion burden than VV ECMO patients. Mortality is greater in the case of extreme transfusion requirements.

Keywords

VV ECMO VA ECMO transfusion outcomes survival complications

Get full access to this article

View all access options for this article.

References

Beckmann

Benk

Beyersdorf

et al . Position article for the use of extracorporeal life support in adult patients. Eur J Cardiothorac Surg 2011; 40: 676–681.

Cheng

Hachamovitch

Kittleson

et al . Complications of extracorporeal membrane oxygenation for treatment of cardiogenic shock and cardiac arrest: a meta-analysis of 1,866 adult patients. Ann Thorac Surg 2014; 97: 610–616.

Lamb

Cowan

Evans

et al . Successful management of bleeding complications in patients supported with extracorporeal membrane oxygenation with primary respiratory failure. Perfusion 2013; 28: 125–131.

Tauber

Streif

Fritz

et al . Predicting transfusion requirements during extracorporeal membrane oxygenation. J Cardiothorac Vasc Anesth 2016; 30: 692–701.

Beckmann

Benk

Beyersdorf

et al . Position article for the use of extracorporeal life support in adult patients. Eur J Cardiothorac Surg 2011; 40: 676–680.

Delnoij

TSR

Driessen

Sharma

Bouman

Strauch

Roekaerts

. Venovenous extracorporeal membrane oxygenation in intractable pulmonary insufficiency: practical issues and future directions. BioMed Res Int 2016; 2016: e9367464.

Sidebotham

McGeorge

McGuinness

Edwards

Willcox

Beca

Extracorporeal membrane oxygenation for treating severe cardiac and respiratory failure in adults: part 2—technical considerations. J Cardiothorac Vasc Anesth 2010; 24: 164–172.

Rastan

Dege

Mohr

et al . Early and late outcomes of 517 consecutive adult patients treated with extracorporeal membrane oxygenation for refractory postcardiotomy cardiogenic shock. J Thorac Cardiovasc Surg 2010; 139: 302–311.e1.

Wang

Han

Jia

et al . Early and intermediate results of rescue extracorporeal membrane oxygenation in adult cardiogenic shock. Ann Thorac Surg 2009; 88: 1897–1903.

10.

Hsu

P-S

Chen

J-L

Hong

G-J

et al . Extracorporeal membrane oxygenation for refractory cardiogenic shock after cardiac surgery: predictors of early mortality and outcome from 51 adult patients. Eur J Cardiothorac Surg 2009; 37: 328–333.

11.

Sidebotham

McGeorge

McGuinness

Edwards

Willcox

Beca

Extracorporeal membrane oxygenation for treating severe cardiac and respiratory disease in adults: part 1—overview of extracorporeal membrane oxygenation. J Cardiothorac Vasc Anesth 2009; 23: 886–892.

12.

Oliver

WC.

Anticoagulation and coagulation management for ECMO. Semin Cardiothorac Vasc Anesth 2009; 13: 154–175.

13.

Tauber

Ott

Streif

et al . Extracorporeal membrane oxygenation induces short-term loss of high-molecular-weight von Willebrand factor multimers. Anesth Analg 2015; 120: 730–736.

14.

Roberts

Jefferson

Economic evaluation and randomised controlled trial of extracorporeal membrane oxygenation: UK collaborative trial. Commentary: concurrent economic evaluations are rare but should be standard practice. BMJ 1998; 317: 911–916.

15.

Kumar

TKS

Zurakowski

Dalton

et al . Extracorporeal membrane oxygenation in postcardiotomy patients: factors influencing outcome. J Thorac Cardiovasc Surg 2010; 140: 330–336.e2.

16.

Aubron

Cheng

Pilcher

et al . Factors associated with outcomes of patients on extracorporeal membrane oxygenation support: a 5-year cohort study. Crit Care 2013; 17: R73.

17.

Flecher

Anselmi

Corbineau

et al . Current aspects of extracorporeal membrane oxygenation in a tertiary referral centre: determinants of survival at follow-up. Eur J Cardiothorac Surg 2014; 46: 665–671.

18.

Whiting

DiNardo

JA.

TEG and ROTEM: technology and clinical applications. Am J Hematol 2014; 89: 228–232.

19.

Mishra

Svennevig

Bugge

et al . Cost of extracorporeal membrane oxygenation: evidence from the Rikshospitalet University Hospital, Oslo, Norway. Eur J Cardiothorac Surg 2010; 37: 339-342.